10-Q: Sensus Healthcare Reports Q2 Loss Amid Revenue Decline

Sensus Healthcare, Inc. reported a significant net loss and revenue decline for the second quarter and first half of 2025, primarily due to lower unit sales to a major customer and increased operating expenses.

Summary

• Revenue decreased by 20.7% to $7.3 million for the three months ended June 30, 2025, compared to $9.2 million in the prior year period.
• For the six months ended June 30, 2025, revenue declined by 21.1% to $15.7 million from $19.9 million in the same period of 2024.
• The company swung to a net loss of $1.0 million for Q2 2025, compared to a net income of $1.6 million in Q2 2024.
• For the first half of 2025, a net loss of $3.6 million was reported, a significant reversal from a net income of $3.9 million in H1 2024.
• Gross profit percentage decreased to 39.7% in Q2 2025 from 58.7% in Q2 2024, and to 46.5% in H1 2025 from 60.8% in H1 2024.
• Operating expenses increased substantially, with research and development (R&D) expense rising by 66.7% in Q2 and 127.8% in H1, partly due to lobbying costs for billing code reimbursement and next-generation system development.
• Cash and cash equivalents remained stable at $22.2 million as of June 30, 2025, a slight increase from $22.1 million at December 31, 2024.
• Net cash provided by operating activities improved to $0.4 million for the six months ended June 30, 2025, compared to net cash used of $4.0 million in the prior year period, primarily driven by a $7.1 million decrease in accounts receivable.
• Inventories increased by $2.3 million to $12.4 million, in anticipation of increasing future sales.
• One U.S. customer accounted for 56% of Q2 2025 revenue and 63% of H1 2025 revenue, and 78% of accounts receivable as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company experienced a substantial decline in revenue and a swing to net loss, driven by lower sales to a key customer and significantly increased operating expenses, particularly in R&D and sales & marketing. Gross profit margins also compressed. While cash from operations turned positive, this was largely due to a reduction in accounts receivable, not increased profitability. The high customer concentration and ongoing legal contingency add to the negative sentiment, despite management's belief in sufficient liquidity for the next 12 months.

Positives

• Net cash provided by operating activities improved significantly to $0.4 million for the six months ended June 30, 2025, a positive swing from a $4.0 million cash outflow in the prior year period.
• Cash and cash equivalents remained stable at $22.2 million as of June 30, 2025, indicating a healthy liquidity position.
• The company is in compliance with all financial covenants under its $15 million revolving credit facility with Comerica Bank.
• Inventory increased by $2.3 million, reflecting management's anticipation of increasing future sales.
• Received $0.3 million in Employee Retention Credits (ERC) in the second quarter of 2025.

Negatives

• Revenue decreased by 20.7% for the three months ended June 30, 2025, and by 21.1% for the six months ended June 30, 2025, primarily due to lower unit sales to a large customer.
• Gross profit declined by 46.3% for the three months and 39.7% for the six months ended June 30, 2025, with gross profit percentage falling from 58.7% to 39.7% (Q2) and 60.8% to 46.5% (H1).
• The company swung from a net income to a net loss of $1.0 million for Q2 2025 and $3.6 million for H1 2025.
• Operating expenses increased significantly across all categories: General and Administrative (up 25.0% Q2), Selling and Marketing (up 40.0% Q2), and Research and Development (up 66.7% Q2, 127.8% H1).
• Increased R&D expenses were attributed to significant lobbying costs related to billing code reimbursement and product development for next-generation systems.
• Accounts receivable decreased by $7.1 million, primarily due to lower sales and extended payment terms with the primary customer.
• Significant customer concentration exists, with one U.S. customer accounting for 56% of Q2 2025 revenue and 78% of accounts receivable as of June 30, 2025.

Risks

• Continued inflationary pressures may impact sales, commodity and shipping prices, and energy and labor costs.
• The level and availability of government and/or third-party payor reimbursement for clinical procedures using products, and the willingness of healthcare providers to purchase products if reimbursement declines.
• Concentration of customers in the U.S. and China, including a significant concentration of sales to one particular customer in the U.S.
• Development by others of new products, treatments, or technologies that could render current technology partially or wholly obsolete.
• Regulatory requirements applicable to the company and its competitors.
• Ability to efficiently manage manufacturing processes and costs.
• Risks arising from doing business in China and other foreign countries.
• Legislation, regulation, or other governmental action that affects products, taxes, international trade regulation (including potential tariffs).
• Performance of information technology systems and ability to maintain data security.
• Ability to obtain and maintain intellectual property needed to adequately protect products, and ability to avoid infringing third-party intellectual property rights.
• An ongoing Department of Justice investigation regarding Medicare billing by a physician who used the SRT-100, with the possibility of expanded investigation into the company's involvement and potential legal action.
• Geopolitical uncertainties, such as the Middle East conflict and the Russian invasion of Ukraine, which are being monitored for potential future impact.

Future Outlook

Management believes that current cash, cash equivalents, borrowing capacity under the existing line of credit, and access to capital resources are sufficient to meet operating capital and funding requirements for the next 12 months. The company anticipates increasing future sales, as indicated by the increase in inventory. Primary short-term capital needs include expanding sales and marketing activities and research and development efforts. Management regularly evaluates cash requirements and may seek to raise additional funds in the future, though there is no assurance regarding the ability to raise such funds or the terms thereof. The company continues to monitor inflationary pressures and is taking actions, such as ordering inventory in advance, to minimize their effects.

Management Comments

• "The decrease [in revenue] was primarily driven by a lower number of units sold to a large customer in the three months ended June 30, 2025 compared to the three months ended June 30, 2024."
• "The increase in cost of sales was primarily related to higher costs of servicing systems and the cost associated with the new placement program."
• "The decrease in gross profit was primarily driven by lower sales, higher costs of servicing systems, and the cost associated with the new placement program."
• "The net increase in general and administrative expense was primarily due to higher professional fees (legal and consult) and compensation."
• "The increase [in selling and marketing expense] was primarily driven by an increase in tradeshow costs, costs related to clinical studies, and payroll cost due to an increase in headcount."
• "The increase [in research and development expense for H1] was primarily due to significant lobbying costs related to billing code reimbursement, increased headcount, and an increase in product development costs related to next generation systems."
• "The decrease [in accounts receivable] was primarily due to the decrease in sales and concentration of sales to the Companys primary customer that is subject to extended payment terms."
• "The increase [in inventories] was primarily due to the anticipation of increasing future sales."
• "The Company believes that proceeds from maturing cash equivalents, as well as the Companys borrowing capacity under its existing line of credit and access to capital resources are sufficient to meet operating capital and funding requirements for the next 12 months from the date of this quarterly report."
• "Sensuss management regularly evaluates cash requirements for current operations, commitments, capital requirements and business development transactions, and may seek to raise additional funds for these purposes in the future."

Industry Context

Operating in the medical device sector, specifically superficial radiation therapy (SRT) for skin conditions, the company's results reflect challenges within this niche, including significant customer concentration and the necessity for substantial investment in R&D for next-generation systems and lobbying for billing code reimbursement. This suggests a dynamic and potentially challenging regulatory and competitive landscape. The company also acknowledges ongoing inflationary pressures impacting its business.

Legal Proceedings

• The company is party to certain legal proceedings in the ordinary course of business.
• Since 2015, the Department of Justice (DOJ) has been investigating Medicare billing by a physician who used the company's SRT-100 device.
• The DOJ is considering expanding the investigation to determine if the company had any involvement in the physician's use of certain reimbursement codes.
• The company has received two Civil Investigative Demands from the DOJ and has fully cooperated.
• The company disputes any wrongdoing, asserting it does not submit claims for reimbursement or provide coding or billing advice to physicians.
• To the company's knowledge, the DOJ has not made a determination regarding wrongdoing or whether to pursue legal action.
• The company believes it has strong and meritorious defenses and will vigorously defend itself if legal action is pursued.
• As of June 30, 2025, the company is unable to estimate the cost, if any, associated with this matter.

Stakeholder Impact

• Shareholders: Negative impact due to significant net loss, decreased revenue, and compressed margins. Potential for future dilution if capital is raised through equity.
• Customers: Potential impact if government and/or third-party payor reimbursement levels decline, affecting their willingness to purchase products. High concentration risk with one large U.S. customer.
• Employees: Increased headcount in sales & marketing and R&D suggests growth in these areas, but overall financial performance could impact future employment stability or compensation.
• Suppliers/Partners: Inflationary pressures and changes in inventory ordering strategies could affect relationships.
• Creditors: The company is in compliance with debt covenants, which is positive, but declining profitability could be a concern if sustained.

Next Steps

• Continue to monitor inflationary pressures and take actions, such as ordering inventory in advance, to minimize their effects on product cost and sales.
• Evaluate the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on future condensed consolidated financial statements and related disclosures.
• Management may seek to raise additional funds for the expansion of sales and marketing activities and research and development activities.
• Continue to monitor developments regarding the Middle East conflict, the Russian invasion of Ukraine, and other geopolitical uncertainties.

Key Dates

Recommendation

The company reported a substantial decline in revenue and a significant swing to net loss, indicating deteriorating operational performance. Gross profit margins have compressed, and operating expenses, particularly R&D, have surged without a corresponding increase in sales. While cash from operations turned positive, this was largely due to a reduction in accounts receivable, not underlying profitability. The high customer concentration and an unresolved Department of Justice investigation add significant risk and uncertainty. These factors suggest a challenging outlook and warrant a cautious approach for investors, leading to a 'sell' recommendation.

Keywords

Sensus Healthcare, SRT-100, Superficial Radiation Therapy, Medical Device, Dermatology, Oncology, Skin Cancer Treatment, Quarterly Report, SEC Filing, Revenue Decline, Net Loss, Operating Expenses, Customer Concentration, Healthcare Reimbursement, Regulatory Risk, DOJ Investigation